VivoSeq
Oncology

Acute Promyelocytic Leukemia

40

Pipeline Programs↗

7

Active Trials↗

23

Companies Involved↗

Acute Promyelocytic Leukemia is a moderately active landscape with 40 programs across 23 companies. The most active players are Syros Pharmaceuticals, Eastern Cooperative Oncology Group, NuRx Pharmaceuticals, Inc.. 13 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

73/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Syros Pharmaceuticals

2 programs

Phase 1E

Eastern Cooperative Oncology Group

2 programs

Phase 2N

NuRx Pharmaceuticals, Inc.

1 program

Phase 2M

McGuff Pharmaceuticals, Inc.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

42 of 46 classified programs — the dominant modality here.

9%ALL OTHERSProtein / enzyme24%Monoclonal antibody12%Antibody–drug conjugate12%

Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 100% of 46 pipeline programs.

Analysis

Trial Status

39

clinical trials

Completed16 · 41%
Unknown status9 · 23%
Recruiting4 · 10%
Terminated3 · 8%
Active, not recruiting2 · 5%
Withdrawn2 · 5%
Other3 · 8%

Clinical Trials

Trial Activity

39 trials

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT05881265·30 enrolled
Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
Recruiting·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT06982274·115 enrolled
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Recruiting·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 2·NCT04793919·89 enrolled
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01409161·151 enrolled
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Active, not recruiting·—·N/A·NCT07187505·28 enrolled
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Active, not recruiting·Children's Oncology Group·Phase 3·NCT02339740·158 enrolled
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Enrolling by invitation·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT06544109·98 enrolled
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Completed·PPETHEMA Foundation·Phase 4·NCT00408278·300 enrolled
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Completed·—·Phase 4·NCT01191541·65 enrolled
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00016159·35 enrolled
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Completed·SWOG Cancer Research Network·Phase 3·NCT00492856·105 enrolled
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
Completed·PPETHEMA Foundation·Phase 4·NCT00465933
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01404949·17 enrolled
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
Completed·Pfizer logoPfizer·Phase 3·NCT00962767·168 enrolled
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Completed·Children's Oncology Group·Phase 3·NCT00866918·106 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)